A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition
NCT ID: NCT06963827
Last Updated: 2025-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
347 participants
INTERVENTIONAL
2025-07-15
2030-01-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will be placed in 1 of the 2 treatment groups; the main group and the open-label group. In the main group, participants will be placed in 1 of the 2 treatment groups by chance (either mezagitamab or placebo) at a 2:1 ratio. This means that out of 3 participants, 2 will receive mezagitamab and 1 will receive placebo. The participants will receive either mezagitamab or placebo for almost half a year in two 1-year cycles. They will be observed for another half year in each 1-year cycle and will have check-ups about every month during this time.
In the open-label group, a small number of participants who have lower levels of protein in their urine or have kidneys that do not filter the blood well, will receive mezagitamab treatment. This will include participants who have previously received mezagitamab in another study, TAK-079-1006. Every participant will receive mezagitamab in the same way as those in the main group receiving mezagitamab.
During the study, participants will visit their study clinic several times.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mezagitamab
Participants will receive mezagitamab injections, subcutaneously (SC), for approximately 22 weeks in each 52-week period.
Mezagitamab
Mezagitamab injections administered SC.
Placebo
Participants will receive mezagitamab-matching placebo injections, SC for approximately 22 weeks in each 52-week period.
Placebo
Mezagitamab-matching placebo injections administered SC.
Open-label Mezagitamab
Participants will receive mezagitamab injections, SC for approximately 22 weeks in each 52-week period.
Mezagitamab
Mezagitamab injections administered SC.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mezagitamab
Mezagitamab injections administered SC.
Placebo
Mezagitamab-matching placebo injections administered SC.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Either UPCR greater than or equal to (≥) 0.8 gram per gram (g/g) or urine protein excretion (UPE) ≥1 grams per day (g/day), calculated from a 24-hour urine collection during the screening period (only applicable for the main group).
2. eGFR greater than (\>)30 milliliters per minute per 1.73 meter square (mL/min/1.73m\^2) at screening based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula (only applicable for the main group).
3. No prior exposure to anti- cluster of differentiation 38 (CD38) therapy period (only applicable for the main group).
4. The participant is at least aged 18 years or the local legal age if greater than 18 years, inclusive.
5. The participant (and the participant's legally acceptable representative, if applicable per local regulations or determination) has provided informed consent (that is, in writing, documented via a signed and dated informed consent form \[ICF\]) and any required privacy authorization before the initiation of any clinical trial procedures.
6. Renal biopsy report supporting diagnosis of primary IgAN within 10 years before signing informed consent for the clinical trial. The redacted report must be made available for review. A renal biopsy may be performed during screening.
7. Participants must be on stable renin-angiotensin-aldosterone system (RAAS) inhibitor therapy with an angiotensin-converting enzyme inhibitor (ACE-I) and/or angiotensin receptor blocker (ARB) or endothelin receptor antagonist (ERA) or mineralocorticoid receptor antagonist (MRA) agent for at least 12 weeks before signing the ICF with dosing at the maximally tolerated or labeled dose as determined by the investigator, with the intent to continue stable dosing during the clinical trial. Those intolerant of RAAS inhibitor therapy are potentially eligible after consultation with the medical monitor. Intolerance is defined as a documented side effect causing discontinuation of the therapy.
8. Women of childbearing potential who are not pregnant during screening (confirmed by negative serum human chorionic gonadotropin \[hCG\]) and on Visit 1 before first dose of trial intervention (confirmed by negative urine pregnancy test).
9. Any one of the following (only applicable for the open-label cohort):
1. Participants in Study TAK-079-1006 who completed the Week 96 visit or the retreatment period with either UPCR \>0.5 g/g or UPE \>0.5 g/d calculated from a 24-hour urine collection during the screening period and eGFR \>30 mL/min/1.73m\^2 at screening based on the CKD-EPI formula.
2. UPCR \<0.8 g/g and UPE ≥0.75 and \<1.0 g/day, by 24-hour urine collection during the screening period and eGFR \> 30 mL/min/1.73m\^2 at screening based on the CKD-EPI formula.
3. UPCR ≥ 0.8 g/g or UPE ≥ 1.0 g/d by 24-hour urine collection during the screening period and eGFR ≥25 and ≤30 mL/min/1.73m\^2 at screening based on the CKD-EPI formula.
Exclusion Criteria
1. Kidney biopsy exhibiting significant concomitant renal disease other than IgAN (for example, diabetic nephropathy, lupus nephritis, minimal change disease).
2. Secondary IgAN (such as with significant liver disease, immunoglobulin A (IgA) vasculitis, inflammatory bowel disease, and seronegative spondyloarthropathies).
3. Evidence of rapidly progressive glomerulonephritis (loss of ≥50% of eGFR within 3 months before the signing of the ICF).
4. Diagnosis of nephrotic syndrome defined as 24-hour proteinuria \>3.5 g/day or hypoalbuminemia (\<3.0 grams per deciliter \[g/dL\]) with or without peripheral edema.
5. Renal or other organ transplantation prior to or expected during the clinical trial.
6. Treatment with oral immunosuppressive agents (including cyclophosphamide, mycophenolate mofetil, cyclosporine, azathioprine, calcineurin inhibitors) or biologic therapy for immunomodulation (including immunomodulatory monoclonal or polyclonal antibodies) within 6 months (both B-cell and non-B-cell directed agents) before signing of the ICF.
7. If the participant has received anti-CD20 treatment, the participant is excluded if either of the following apply:
1. The last dose was received within 6 months before the signing of the ICF.
2. The last dose was received between 6 and 12 months before the signing of the ICF and the participant has a CD19+ count below the lower limit of normal.
Note: Participants who have received the last dose of anti-CD20 treatment \>12 months before the signing of the ICF are not excluded from clinical trial participation based on this criterion and are not required to undergo CD19+ testing.
8. Use of systemic corticosteroids at an average dose of 40 milligrams (mg) prednisone equivalent or higher for more than 14 days within 4 months of the screening visit, or use of oral budesonide delayed release capsules within 1 year of the screening visit.
9. The participant has received a live or live-attenuated vaccine within 4 weeks before signing the ICF or has any live or live-attenuated vaccine planned during the clinical trial.
10. Participation in any other investigational drug trial (including vaccine trial) with receipt of at least 1 dose of investigational drug, or has been exposed to another investigational agent within 4 weeks or 5 half-lives, whichever is longer, before Visit 1.
11. The participant has active infection with hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).
12. The participant has had any of the following types of infections within the specified timeframes where applicable:
1. Active bacterial, viral, fungal infection (except for the common cold and onychomycosis), or any other serious infection within 2 weeks of signing the ICF. Any anti-infective course for infection must be completed at least 2 weeks before Visit 1.
2. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) infection within 4 weeks of signing the ICF.
3. Opportunistic infection or treatment for an opportunistic infection lesser than or equal to (≤)12 weeks before signing the ICF.
13. In the opinion of the investigator, the participant is currently experiencing any medical condition that might interfere with participation in the trial (for example, significant ocular, cardiovascular, pulmonary, hematologic, gastrointestinal, endocrinologic, hepatic, renal, neurologic, malignancy, infectious disease, immunodeficiency, or alcohol and drug abuse), that poses an added risk for the participant or could confound the assessment of trial results.
14. In the opinion of the investigator, the participant has a serious medical or psychiatric illness that could potentially interfere with the completion of treatment.
15. The participant has a history of major surgery within 3 months before screening (or longer, at the discretion of the investigator); or, either has a planned tonsillectomy or underwent a tonsillectomy within 6 months before screening.
Note: Major surgery typically requires at least 1 night in the hospital.
16. History of malignancy (including myelodysplastic syndrome) within 5 years of signing the ICF, except for adequately treated non-melanoma skin cancer, superficial bladder cancer, and curatively treated cervical carcinoma-in-situ.
17. The participant has a history of a severe allergic or anaphylactic reaction to recombinant proteins or excipients used in the mezagitamab or placebo formulation.
18. The participant has (1) been diagnosed with or has suspected chronic obstructive pulmonary disease (COPD) or asthma and (2) has a prebronchodilatory forced expiratory volume in 1 second (FEV1) \<50% of predicted normal at screening.
19. The participant is capable of breastfeeding but does not agree to forego breastfeeding from first dose of investigational medicinal product (IMP) through 30 days after the last dose of IMP.
20. The participant is an individual with potential for pregnancy but does not agree to use at least 1 form of highly effective contraception and 1 barrier method of contraception (preferably male condom) when engaging in heterosexual sex for the protocol specified duration after the last dose of IMP.
21. The participant is a sexually active, non-sterilized individual who produces sperm but does not agree to use a barrier method (preferably male condom) combined with at least 1 form of highly effective contraception for any partner(s) with potential for pregnancy when engaging in heterosexual sex for the protocol specified duration after the last dose of IMP.
22. In the investigator's opinion, the participant (and the participant's legally acceptable representative, if applicable per local regulations or determination) is unwilling and/or unable to understand and fully comply with clinical trial procedures and requirements (including digital tools and applications).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
Takeda
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
DCR Montgomery
Montgomery, Alabama, United States
Academic Medical Research Institute
Los Angeles, California, United States
South Florida Research Institute
Lauderdale Lakes, Florida, United States
Bioresearch Partners
Miami, Florida, United States
CTR Oakwater, LLC
Orlando, Florida, United States
Bioresearch Partners
Pembroke Pines, Florida, United States
DCR Columbus
Columbus, Georgia, United States
CARE Institute - Boise Kidney
Boise, Idaho, United States
Northwest Louisiana Nephrology
Shreveport, Louisiana, United States
DCR Edina
Edina, Minnesota, United States
Clinical Research Consultants a JCCT Company
Kansas City, Missouri, United States
DCR - El Paso
El Paso, Texas, United States
Provecta Research Network
Houston, Texas, United States
Nephrology Associates of Houston PLLC
Katy, Texas, United States
Sun Research Institute
San Antonio, Texas, United States
West Virginia University
Morgantown, West Virginia, United States
Peking University First Hospital
Beijing, Beijing Municipality, China
Zhongshan Hospital Xiamen University
Xiamen, Fujian, China
Guangdong General Hospital
Guangzhou, Guangdong, China
The Third Xiangya Hospital of Central South University Yuelu District
Changsha, Hunan, China
The First Affiliated Hospital of Baotou Medical College
Baotou Shi, Inner Mongolia, China
Zhongda Hospital Southeast University
Nanjing, Jiangsu, China
Affiliated Hospital of Nantong University
Nantong, Jiangsu, China
Wuxi People's Hospital
Wuxi, Jiangsu, China
Shandong University - Qilu Hospital
Jinan, Shandong, China
West China Hospital Sichuan University
Chengdu, Sichuan, China
Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
Qingyang District, Chengdu, Sichuan, China
The Second People's Hospital of Yibin
Yibin, Sichuan, China
The First Affiliated Hospital of Ningbo University
Ningbo, Zhejiang, China
The University of Hong Kong - Department of Medicine
Hong Kong, Hong Kong Island, Hong Kong
Kasugai Municipal Hospital
Kasugai-Shi, Aichi-ken, Japan
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital
Nagoya, Aichi-ken, Japan
Fujita Health University Hospital
Toyoake-shi, Aichi-ken, Japan
National Hospital Organization Chiba Medical Center Chibahigashi National Hospital
Chiba, Chiba, Japan
Kyushu University Hospital
Fukuoka, Fukuoka, Japan
Fukushima Medical University Hospital
Fukushima, Fukushima, Japan
Hiroshima University Hospital
Hiroshima, Hiroshima, Japan
Hokkaido University Hospital
Sapporo, Hokkaido, Japan
Shonan Kamakura General Hospital
Kamakura-shi, Kanagawa, Japan
Yokohama City University Hospital
Yokohama, Kanagawa, Japan
Japan Community Health care Organization Sendai Hospital
Sendai, Miyagi, Japan
Nara Medical University Hospital
Kashihara-shi, Nara, Japan
Nara Prefecture General Medical Center
Nara, Nara, Japan
Oita University Hospital
Yufu-shi, Oita Prefecture, Japan
Dokkyo Medical University Saitama Medical Center
Koshigaya-shi, Saitama, Japan
Juntendo University Hospital
Bunkyo-ku, Tokyo, Japan
Tokyo Medical University Hospital
Shinjuku-Ku, Tokyo, Japan
University Hospital Zurich
Zurich, , Switzerland
King's College Hospital
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Ahmad SB, Jefferson JA. Targeting B Cells and Plasma Cells in Glomerular Disease. J Am Soc Nephrol. 2025 Jun 4;36(9):1844-1857. doi: 10.1681/ASN.0000000772.
Related Links
Access external resources that provide additional context or updates about the study.
Click here for more information about this trial in easy-to-understand language, including a Plain Language Summary of the results if the trial has been completed.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-520825-19-00
Identifier Type: CTIS
Identifier Source: secondary_id
TAK-079-3001
Identifier Type: -
Identifier Source: org_study_id